Get started

Researchanddevelopment

Boston Scientific Fundamental Strength and Technical BreakoutBoston Scientific develops, manufactures, and markets medical devices. Q4 earnings were reported this week providing a clear picture of 2022 annual fundamentals. The fundamentals considered are presented on the chart with brief commentary. Technical considerations: Price bounced off of trend line going back to 2012 Ascending triangle breakout New ATH weekly close Positions: Entry: 100 shares @ $48.71 Target: $67.43 by July 2025 Stop: $44.19 (~20-week SMA, below 2023 low) R/R: 4.14 Reward: $1872 Risk: $452 Time Horizon: 12+ months Current price (weekly close): $48.50 Risk Analysis Chart: Main chart before distorted by publishing process:
NYSE:BSXLong
by Skipper86
META needs to cut back on R&DR&D spending on the metaverse and other projects is eating into net income. Revenue is still impressive. People still use Facebook and Instagram. With a P/E of 8.649 nearing the bottom of a parallel channel drawn on the log scale chart, I can’t help but think there’s an options play or even a great long-term buying opportunity waiting to be had some time over the next 6 months. If Meta stops wasting money on pie-in-the-sky R&D endeavors, their financials will look a lot better. I need to further analyze the technicals to try and find support and anticipate timing but for now this is my pre-assessment of the situation.
NASDAQ:META
by Skipper86